EPIC DROP in a Stable Company Top 5 thoughts
-----
1. has real cash
2. has low cost debt
3. has real customers
4. serves a need
5. The quarterly results in no way corresponds to the market sell off
Dexcom
Dexcom Plummets 10% on Raising Its Sales Guidance For The Year Dexcom ( NASDAQ:DXCM ) stock ended Friday's trading session on a rough slate despite the company's first-quarter beat and boosted sales guidance.
Sales guidance, however, was light at the midpoint and Dexcom ( NASDAQ:DXCM ) stock plummeted 10%, closing at 124.34. easily boycotting a recent buy point at 132.03 out of a flat base.
Some analysts noted that the lion's share of Dexcom's first-quarter growth came from its international segment, while U.S. sales were largely in line with historical seasonal trends. Dexcom ( NASDAQ:DXCM ) makes continuous glucose monitors, or CGMs. These body-worn devices help people with diabetes keep tabs on their blood sugar in real time — a critical component to managing the disease.
Dexcom Stock: Solid Beat
In the first quarter, Dexcom's ( NASDAQ:DXCM ) sales surged 24% to $921 million. Organically, sales climbed 25% year over year. That easily beat expectations for $910 million, according to FactSet.
Further, adjusted earnings came in at 32 cents per share, a nickel above forecasts, and nearly double the 17 cents a share the company reported in the year-earlier period.
Dexcom ( NASDAQ:DXCM ) also raised the lower boundary of its guidance for the year, and now expects $4.2 billion to $4.35 billion in sales. The midpoint is slightly below Dexcom stock analysts' forecast for $4.33 billion.
Dexcom ( NASDAQ:DXCM ) further noted a record number of new patients started using Dexcom's CGMs during the first quarter and there's been "significant interest" in Stelo, Andrew said. Stelo, Dexcom's newest CGM, will launch this summer for patients with type 2 diabetes who don't require insulin treatment. The device will be available without a prescription, meaning it will likely see some uptake among non-diabetics.
DXCM DexCom Options Ahead of EarningsAnalyzing the options chain and the chart patterns of DXCM DexCom prior to the earnings report this week,
I would consider purchasing the 137usd strike price Calls with
an expiration date of 2024-5-3,
for a premium of approximately $5.95.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Dexcom Bullish - pre earningsI would place a limit buy order if it retest downwards. Earnings on Thursday and common positive outlook by analysts.
DexCom: Potential Early Bearish C EntryDexCom appears to be in a Diamond Pattern while showing big MACD Hidden Bearish Divergence on the Weekly Timeframe that could later lead to a Confirmed ABCD/Gartley BAMM Harmonic breakdown upon the breaking the B point which from there likely could take it down to the Pattern Completion Zone of $30.64.
I will be playing this via the currently slightly OTM: FEB and MARCH $100 Striked Puts.
DexCom to breakdown?DexCom - 30d expiry - We look to Sell a break of 108.48 (stop at 113.03)
We are trading at overbought extremes.
Although the bulls are in control, the stalling positive momentum indicates a turnaround is possible.
A break of the recent low at 108.68 should result in a further move lower. This stock has seen poor sales growth.
Levels above 122 continue to attract sellers.
Our profit targets will be 97.11 and 95.11
Resistance: 118.00 / 120.00 / 125.55
Support: 108.68 / 105.00 / 100.00
Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Signal Centre’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Signal Centre.
DexcomI will try my chances at current price which is weekly 50EMA
If doesnt hold will take another shot at weekly 200EMA
No stop loss for this stock. I prefer to average my entry.
June 22 2020 – Top Stocks To Buy And Watch This WeekJune 22 2020 – Top Stocks To Buy And Watch This Week
Go to the Invest2Success Blog and or Contact Me for the Details
NASDAQ:DXCM
NASDAQ:FIVN
NYSE:WST
NYSE:TDOC
NASDAQ:WING
NYSE:ABT
NYSE:MDT
NASDAQ:TNDM
NASDAQ:PODD
NYSE:RNG
NYSE:TWLO
NASDAQ:ZM
NASDAQ:MSFT
NYSE:EPAM
NYSE:NET
$DXCM #Dexcom $FIVN #Five9 $WST #WestPharmaceutical $TDOC #TeladocHealth $WING #Wingstop $ABT #AbbottLabs $MDT #Medtronic $TNDM #TandemDiabetes $PODD #Insulet $RNG #RingCentral $TWLO #Twilio $ZM #ZoomCommunications $MSFT #Microsoft $EPAM #EpamSystems $NET #CloudFlare #coronavirus #financialforecast #stocks #stockstowatch #stockmarket #wallstreet #nyse #sp500 #investing #investors #trading #traders #elliottwave #markets #finance #economy #semiconductors #technology
DEXCOM Buying Opportunities May Lies Below 360Great Stocks that have been showing good upside momentum is now on pullback. A re-test of its recent swing low (with rejection) may provide a good buying opportunity.
N.B
- Let emotions and sentiments work for you
-ALWAYS Use Proper Risk Management In Your Trades
$DXCM: $375 Price Target ShortFirst off, please don't take anything I say seriously or as financial advice. As always, this is on opinion basis. That being said, let me get into a few key points. Dexcom very recently faced a 52 week high, had positive quarterly earnings, is on a bullish run, outperformed other stocks in the same sector, continues stable growth and has a strong buy rating. It does have some long potential as well, given it is a 2800+ employee company. However, given its long bullish run, I think there is a small chance it could be tipping off. That being said, for a quick profit target, I suggest a $375 short and a reinvestment in some higher growth (but maybe higher risk) stocks.
DEXCOM $DXCMDexcom broke apart the resistance with great volume. RSI hit the resistance but the volume may give power for next week. Watch for RSI
Dexcom Shares: Potential 8x Rise Next 3 YearsRecently shares of the Dexcom Inc., that are traded on the NASDAQ exchange, probably have made the bottom and started a new uptrend. Dexcom is a medical device company. The company is focused on development of continuous glucose monitoring systems. Let's look at the price movements of this stock (which is traded at $85.13 now) from the technical point of view. Here is the monthly chart.
Clear motive Elliott Wave structure
There is a pretty clear and obvious motive Elliott Wave structure here, started in 2009.
The top of the wave 1 occured in April 2011, followed by the mid-term downtrend presented by the wave 2 (a zigzag pattern), which was ended in November 2011. After that, the motive wave 3 took place till September 2015. And in the September 2015 - December 2016 period we can see the wave 4 that seems like a "running flat" correction pattern. And there is a high possibility of the new motive wave 5 beginning right now.
And everything fits into a correct trend channel.
Wave symmetry
Wave 1 had 1,147% growth and 29 months length.
Wave 3 had 1,417% growth and 46 months length.
The coming wave 5 should have the same or comparable percentage of growth and the same or comparable length. So there is a high possibility of at least 1,100% growth in the next 3 years, compared to the recent bottom at $57. The calculated price target is around $600 by 2020.
Trend channel
By the trend channel rules, we can see the similar price and time targets.
The price is likely to make the next top at the upper line of the trend channel, which shows us ~$680 somewhere in 2020.
Moreover, the trend channel can help us to recognize early if the forecast is incorrect: in the unlikely case the price fails to reach the target and falls below the lower line of the trend channel, then this wave structure will become invalid and we need to re-analyse it and get out of the market.
The year 2020. Again.
Dexcom is another asset that is gonna have long-term reversal in 2020. See my previous articles:
US Dollar Index Likely to Make Grand Top in 2020
The best time to invest in Dubai will be the year 2020
